← Compound index
COMPOUND RECORD / GLANDOKORT

GlandokortГландокорт

A peptide mixture extracted from calf or pig adrenal glands, studied in an institute report on stress-related hormones.

Source linked

What the studies found

Comparison in people · 2011

Glandokort: clinical report on a tissue-derived preparation

Plasma aldosterone in the adrenal-insufficiency table
38.5 ± 1.3 pg/mL with Glandokort versus 26.2 ± 1.6 pg/mL with conventional care. Shared baseline 14.7 ± 1.2 pg/mL.
Cortisol in the prolonged-stress table
431.4 ± 25.7 versus 311.4 ± 21.4 nmol/L. Shared baseline 287.5 ± 18.5 nmol/L.
ACTH in the prolonged-stress table
28.6 ± 1.1 versus 17.4 ± 1.3 pg/mL. The table gives no significance mark for ACTH.

In the adrenal-insufficiency table, plasma aldosterone was 38.5 versus 26.2 pg/mL after adjunctive Glandokort and conventional care, respectively. The subgroup sizes are unclear.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 36 patients described; 26 controls separately stated. Enrollment denominator unresolved.

Design The report mentions 36 patients and separately describes 26 controls. Assignment and subgroup sizes are unclear. The adjunctive schedule was one 10 mg capsule orally with meals twice daily (20 mg/day) for 30 days. The report excluded patients receiving hormone therapy.

Important limitations

  • Resolve enrollment and diagnostic criteria before pooling participants. Hormone-marker changes cannot establish a treatment for nonspecific fatigue. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
  • The tables mark aldosterone and cortisol as significant against conventional care. Subgroup sizes and the relationship of the 26 controls to the 36 described patients are unclear.

Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date · Institute report — commercial reproduction

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Glandokort

Identity / background source ↗

Research background

Glandokort is an adrenal tissue peptide preparation. A Medical Center report measured hormone levels during short-term treatment.

Compound class
Tissue-derived peptide preparation
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

36 patients described; 26 controls separately stated. Enrollment denominator unresolved.

Study methods

Small comparative institute report; allocation, blinding and outcome interpretation require caution

Independent replication

Independent replication not established in this collection

Source access

Report reproduction linked; source language and review scope shown per record

Safety evidence

Short-term reports do not establish long-term safety or equivalence to current products

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Comparison in people · 2011

Glandokort: clinical report on a tissue-derived preparation

In the adrenal-insufficiency table, plasma aldosterone was 38.5 versus 26.2 pg/mL after adjunctive Glandokort and conventional care, respectively. The subgroup sizes are unclear.

Plasma aldosterone in the adrenal-insufficiency table · 38.5 ± 1.3 pg/mL with Glandokort versus 26.2 ± 1.6 pg/mL with conventional care. Shared baseline 14.7 ± 1.2 pg/mL.

Study notes and original source
2011Human comparative studyFull text available

Glandokort: clinical report on a tissue-derived preparation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date

In the adrenal-insufficiency table, plasma aldosterone was 38.5 versus 26.2 pg/mL after adjunctive Glandokort and conventional care, respectively. The subgroup sizes are unclear.

Results and tables

Reported findings and study design

The report mentions 36 patients and separately describes 26 controls. Assignment and subgroup sizes are unclear. The adjunctive schedule was one 10 mg capsule orally with meals twice daily (20 mg/day) for 30 days. The report excluded patients receiving hormone therapy.

Population or model 36 patients described; 26 controls separately stated. Enrollment denominator unresolved.

Results · Russian Medical Center report, PDF pages 32–33, Tables 1–2
MeasureResultComparison, timing and statistics
Plasma aldosterone in the adrenal-insufficiency table38.5 ± 1.3 pg/mL with Glandokort versus 26.2 ± 1.6 pg/mL with conventional care. Shared baseline 14.7 ± 1.2 pg/mL.
Cortisol in the prolonged-stress table431.4 ± 25.7 versus 311.4 ± 21.4 nmol/L. Shared baseline 287.5 ± 18.5 nmol/L.
ACTH in the prolonged-stress table28.6 ± 1.1 versus 17.4 ± 1.3 pg/mL. The table gives no significance mark for ACTH.

The tables mark aldosterone and cortisol as significant against conventional care. Subgroup sizes and the relationship of the 26 controls to the 36 described patients are unclear.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
36 patients described; 26 controls separately stated. Enrollment denominator unresolved.
Source reviewed
Russian Medical Center report, PDF pages 32–33, methods and hormone tables.
Study limitations
  • Resolve enrollment and diagnostic criteria before pooling participants. Hormone-marker changes cannot establish a treatment for nonspecific fatigue.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Reviewed 2026-11-16.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗